ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• ProQR Therapeutics N.V. has received a consensus rating of "Moderate Buy" from analysts, with estimates suggesting an average price target of $8.00.
• The company reported a loss of $0.14 per share for the latest quarter, missing the consensus estimate and revealing a negative net margin of 238.52%.
• Institutional investors hold about 32.65% of ProQR Therapeutics' stock, with several hedge funds recently increasing their stakes in the company.

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $8.00.

PRQR has been the subject of several research analyst reports. Evercore ISI reaffirmed an "outperform" rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of ProQR Therapeutics in a research report on Saturday, September 27th. JMP Securities restated a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. Cantor Fitzgerald restated an "overweight" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. Finally, Chardan Capital restated a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday, August 8th.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds have recently made changes to their positions in PRQR. Jane Street Group LLC acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth $30,000. Bank of America Corp DE boosted its holdings in ProQR Therapeutics by 11.8% in the fourth quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company's stock valued at $217,000 after acquiring an additional 8,621 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in ProQR Therapeutics in the first quarter valued at $48,000. OneDigital Investment Advisors LLC boosted its holdings in ProQR Therapeutics by 45.5% in the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 12,500 shares during the last quarter. Finally, Monaco Asset Management SAM boosted its holdings in ProQR Therapeutics by 59.1% in the first quarter. Monaco Asset Management SAM now owns 471,908 shares of the biopharmaceutical company's stock valued at $628,000 after acquiring an additional 175,290 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $2.27 on Wednesday. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.62. The company has a market capitalization of $238.83 million, a P/E ratio of -4.93 and a beta of 0.23. The business has a 50 day moving average price of $2.17 and a 200 day moving average price of $1.89.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. The firm had revenue of $4.33 million during the quarter, compared to analysts' expectations of $5.01 million. On average, research analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.